Welcome to our dedicated page for Elanco Animal Health news (Ticker: ELAN), a resource for investors and traders seeking the latest updates and insights on Elanco Animal Health stock.
Elanco Animal Health Incorporated (NYSE: ELAN) is a global animal health company focused on products and services that prevent and treat disease in farm animals and pets. The ELAN news feed on Stock Titan aggregates company announcements, regulatory updates and other disclosures so readers can follow how Elanco’s strategy and product portfolio evolve over time.
Elanco regularly issues news on pet health innovations, including prescription products for dogs and cats. Recent press releases have covered developments in canine dermatology, such as Zenrelia tablets for control of itching and inflammation associated with skin allergies in dogs and Befrena, an injectable monoclonal antibody targeting canine allergic and atopic dermatitis. The company also reports on its Credelio and Credelio Quattro brands for parasite control in dogs and Credelio CAT for cats, including label expansions, emergency use authorizations and new indications such as protection related to Lyme disease and emerging tick species.
Investors and industry followers will also find farm animal and corporate updates, including quarterly financial results, guidance, restructuring plans and productivity initiatives like Elanco Ascend. News items describe trends in pet health and farm animal revenue, progress in innovation pipelines, changes to manufacturing and R&D footprints, and participation in major healthcare and investor conferences.
This ELAN news page helps readers track how Elanco’s innovation, portfolio and productivity strategy is reflected in product approvals, regulatory milestones, financial performance and strategic partnerships. For anyone monitoring animal health markets, veterinary therapeutics or ELAN stock, it provides a centralized view of the company’s most recent public communications.
AgBiome has appointed Dr. Marijn Dekkers as Chairman of the Board, effective January 1, 2021. Dekkers, a former CEO of Bayer AG and Thermo Fisher Scientific, will leverage his extensive experience to guide AgBiome's growth strategies. Notably, AgBiome is focused on developing natural crop protection products through its proprietary GENESIS™ discovery platform, targeting a significant market opportunity valued at 100 billion dollars. The company also collaborates with Elanco Animal Health to create nutritional health solutions for swine.
Elanco Animal Health (NYSE: ELAN) announces that Sarena Lin, executive VP of Transformation and Technology, will leave the company at the end of January. Lin has played a crucial role in integrating Bayer's animal health business, achieving $300 million in synergies ahead of schedule. As Elanco progresses through its Innovation, Productivity, and Portfolio strategy, responsibility for finance and integration will shift to CFO Todd Young. The company anticipates eight product launches in 2021, with one potentially being a blockbuster, alongside targeted cost savings of $100 million.
Elanco Animal Health (NYSE: ELAN) will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 12, 2021. Jeff Simmons, president and CEO, is scheduled to present at 7:30 a.m. ET and will engage with analysts during the session. A live audio webcast will be accessible in the company's investor section, with a replay available for 90 days. Elanco is committed to enhancing animal health and welfare through innovative products and services, aiming to make a positive impact on society.
Elanco Animal Health (NYSE: ELAN) held its Investor Day today, showcasing an enhanced Innovation, Portfolio, Productivity (IPP) strategy aimed at achieving revenue growth targets. CEO Jeff Simmons emphasized planned annual revenue growth of 3%-4% and adjusted EBITDA and EPS growth. Key highlights include eight expected product launches in 2021, projected revenue additions of $80-150 million, and $300 million in synergies from the Bayer acquisition by 2023. The company raised Q4 2020 revenue guidance to $1,040-$1,070 million, and provided 2021 guidance of $4,520-$4,600 million, despite facing a $70-$75 million impact from antitrust divestitures.
Elanco Animal Health has appointed William F. Doyle, alongside Scott Ferguson and Paul Herendeen, to its Board of Directors. This expansion is part of a strategic move to enhance innovation and operational oversight, particularly following the Bayer Animal Health acquisition. The company will also establish a new Innovation, Science and Technology Committee and an independent Advisory Board to bolster R&D efforts. The Finance Committee's role was expanded to focus on operational initiatives and financial oversight, underlining Elanco's commitment to shareholder value creation amidst integration challenges.
Kindred Biosciences, Inc. (NASDAQ: KIN) announced a partnership granting Elanco Animal Health exclusive global rights to its monoclonal antibody, KIND-030, targeting canine parvovirus (CPV). KindredBio will receive an upfront payment of $500,000 and potential milestone payments totaling $16 million for development and $94 million in sales milestones. Currently, there are no approved treatments for CPV, which affects about 250,000 dogs annually in the U.S. This collaboration aims to enhance market access for KIND-030.
Elanco Animal Health has agreed to acquire exclusive global rights to KIND-030, a novel monoclonal antibody for treating and preventing canine parvovirus (CPV). This disease affects over 250,000 puppies annually in the U.S. and currently has no approved treatment. The agreement includes a $500,000 upfront payment and potential milestone payments tied to development success. The pivotal efficacy study for the therapeutic indication is expected to conclude in Q1 2021, enhancing Elanco's vaccine and therapeutics portfolio.
Elanco Animal Health (NYSE: ELAN) has chosen Indianapolis, Indiana, for its new global headquarters, a move designed to enhance operational efficiency following its acquisition of Bayer's animal health business. The state has provided a competitive incentive package involving retention of 1,600 jobs and the creation of over 570 new jobs in the next decade. The $100M campus is expected to yield cost savings and improve cash flow. Elanco aims to further its Innovation, Portfolio, and Productivity strategy while contributing positively to the local community and economy.
Elanco Animal Health (NYSE: ELAN) will host a virtual investor day on December 15, 2020, beginning at 10:00 AM ET. Presentations will be led by CEO Jeff Simmons and other executives, focusing on strategies for long-term shareholder value and 2021 financial guidance. The event will include a live Q&A session. Interested parties can register via the investor website, and a replay will be available for one year following the event.
Elanco Animal Health announced a public offering of 54,500,000 shares of its common stock at $30.25 per share, solely held by Bayer World Investments B.V. Bayer has granted underwriters an option to purchase an additional 8,175,000 shares. Elanco will not issue any shares nor receive proceeds from this offering, which is set to close around December 3, 2020. The offering will proceed under Elanco's existing registration statement with the SEC, with BofA Securities, Goldman Sachs, and Credit Suisse serving as joint book-running managers.